Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $5.2 million.

  • Biodesix's Change in Receivables rose 38101.13% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 1816.09%. This contributed to the annual value of $1.8 million for FY2024, which is 6161.51% down from last year.
  • Latest data reveals that Biodesix reported Change in Receivables of $5.2 million as of Q3 2025, which was up 38101.13% from -$181000.0 recorded in Q2 2025.
  • In the past 5 years, Biodesix's Change in Receivables ranged from a high of $5.2 million in Q3 2025 and a low of -$13.1 million during Q2 2021
  • Moreover, its 5-year median value for Change in Receivables was $325000.0 (2024), whereas its average is $37631.6.
  • In the last 5 years, Biodesix's Change in Receivables crashed by 576493.51% in 2021 and then surged by 700303.03% in 2024.
  • Biodesix's Change in Receivables (Quarter) stood at $873000.0 in 2021, then dropped by 15.69% to $736000.0 in 2022, then skyrocketed by 380.98% to $3.5 million in 2023, then plummeted by 71.72% to $1.0 million in 2024, then soared by 421.88% to $5.2 million in 2025.
  • Its Change in Receivables stands at $5.2 million for Q3 2025, versus -$181000.0 for Q2 2025 and -$904000.0 for Q1 2025.